During the past decade, Brigham and Women's Hospital conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 11 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 7 clinical trials were completed. i.e. 77.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Brigham and Women's Hospital" #1 sponsor was "Brigham and Women's Hospital" with 8 trials, followed by "Pfizer" with 4 trials sponsored, "Shire" with 4 trials sponsored, "Fred Hutchinson Cancer Center" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Brigham and Women's Hospital" #1 collaborator was "Brigham and Women's Hospital" with 2 trials as a collaborator, "Bright Research Partners" with 2 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 2 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator and "National Center for Complementary and Integrative Health (NCCIH)" with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Brigham and Women's Hospital" are "Chronic Pain" (3 trials), "Crohn's Disease" (3 trials), "Hereditary Angioedema (HAE)" (3 trials), "Chronic Low Back Pain" (2 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "Brigham and Women's Hospital" in a lesser frequency.

Most popular intervention types in "Brigham and Women's Hospital" are "Drug" (16 trials), "Device" (9 trials), "Behavioral" (4 trials), "Biological" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "ecallantide" (3 trials), "Golimumab" (2 trials), "Guselkumab" (2 trials) and "JNJ-78934804" (2 trials). Other intervention names were less common.

The vast majority of trials in "Brigham and Women's Hospital" are 28 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Brigham and Women's Hospital". 1 are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Brigham and Women's Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Brigham and Women's Hospital, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 14 trials that are defined as “Not Applicable".